News | July 23, 2025
Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Overall investment in the US facility is estimated around US$50 million
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Subscribe To Our Newsletter & Stay Updated
